Amarantus Bioscience Holdings Inc (AMBS)

[MUKA1]

Something could be mentioned by Marks, but doubtful for the same reasons that Gerald wouldn't comment on any ongoing relations with MJFF. Marks was part of the MJFF Neurotrophic Factors discussion earlier this year and nothing was mentioned specifically about MANF....although that was the discussion where a "cocktail" therapeutic approach was a consideration.

What is more important in my mind is that:
"Amarantus has a relationship with Renishaw through a grant application with the Michael J. Fox Foundation, so it would not surprise us to see Amarantus team up with Renishaw later this year."
From Jason's AMBS Zack's Report, 5/22/13, pg. 13

This is not dot connecting...just the facts-
-LOI has been signed with Renishaw for CED delivery
-MJFF grant application for CED/MANF research has been submitted
-

This is dot connecting and positive speculation...
-MJFF is not done with Amarantus/MANF

On May 22, 2013, the Company entered into a letter of intent to in-license a Phase 2 drug candidate in L-Dopa-Induced Dyskinesia Parkinson's Disease from an undisclosed third party. Once licensed the Company intends to initiate a Phase 2b clinical trial within 12 months. June 13, 2013 8k ...Eltoprazine

-Previous recipient of this program was Psychogenics with their work with Eltoprazine

-New board member David Lowe...with ties to Psychogenics.

-4th quarter MJFF Partnering Program awards are due any day.